- Home
- LGVN vs MRKR Comparison
LGVN vs MRKR Comparison
Compare LGVN & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- MRKR
- Stock Information
- Founded
- LGVN 2014
- MRKR N/A
- Country
- LGVN United States
- MRKR United States
- Employees
- LGVN N/A
- MRKR N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- MRKR Health Care
- Exchange
- LGVN Nasdaq
- MRKR Nasdaq
- Market Cap
- LGVN 25.2M
- MRKR 21.9M
- IPO Year
- LGVN 2021
- MRKR N/A
- Fundamental
- Price
- LGVN $1.56
- MRKR $1.57
- Analyst Decision
- LGVN Strong Buy
- MRKR Strong Buy
- Analyst Count
- LGVN 3
- MRKR 1
- Target Price
- LGVN $8.67
- MRKR $19.00
- AVG Volume (30 Days)
- LGVN 161.2K
- MRKR 94.9K
- Earning Date
- LGVN 02-28-2025
- MRKR 03-25-2025
- Dividend Yield
- LGVN N/A
- MRKR N/A
- EPS Growth
- LGVN N/A
- MRKR N/A
- EPS
- LGVN N/A
- MRKR N/A
- Revenue
- LGVN $1,852,000.00
- MRKR $5,395,849.00
- Revenue This Year
- LGVN $208.32
- MRKR $64.48
- Revenue Next Year
- LGVN $43.96
- MRKR N/A
- P/E Ratio
- LGVN N/A
- MRKR N/A
- Revenue Growth
- LGVN 141.46
- MRKR 79.04
- 52 Week Low
- LGVN $0.77
- MRKR $1.48
- 52 Week High
- LGVN $6.40
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- LGVN 45.58
- MRKR 35.08
- Support Level
- LGVN $1.53
- MRKR $1.53
- Resistance Level
- LGVN $1.71
- MRKR $1.79
- Average True Range (ATR)
- LGVN 0.13
- MRKR 0.18
- MACD
- LGVN 0.02
- MRKR 0.03
- Stochastic Oscillator
- LGVN 38.30
- MRKR 14.52
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.